Fig 1: Characteristics of ALX4 and WDR86. a, e The expression of ALX4 or WDR86 in pre-menopausal normal (blue), post-menopausal normal (red), and tumor (green) samples in TCGA dataset. b, f The expression of ALX4 or WDR86 in normal tissues in the GTEx dataset. c, g The paired comparison of ALX4 or WDR86 between matched tumors and normal tissues in TCGA dataset. d, h The predictive powder of ALX4 or WDR86 for relapse-free survival of all and different subtypes of breast cancer patients
Fig 2: Effect of the overexpression of ALX4 and WDR86 on the malignant properties of BT-474 and MDA-MB-231 cells. Growth of breast cancer cells of BT-474 (a) and MDA-MB-231 (b). Migration capacity of breast cancer cells of BT-474 (c) and MDA-MB-231 (d). Colony-forming capacity of breast cancer cells of BT-474 (e) and MDA-MB-231 (f). Comparison of tumor volume over time (g) and final tumor weight (h) between control and ALX4- or WDR86-overexpressing BT-474 cell-inoculated mice. Data are presented as the mean ± sem from three measurements (a–f) or nine tumors (g, h). Two-sample t tests were used to compare the means of the control and each knockdown group.*P < 0.05; **P < 0.005
Supplier Page from DNASU for ALX4 (Homo sapiens) in pENTR223.1 (Gateway donor/master vector)